Podcasts about wakelee

Dr. Bryant Lin is a primary care physician, educator, and researcher at Stanford University. In 2018, he founded CARE – the Center for Asian Health Research and Education. In 2023, CARE began a focused research effort investigating lung cancer in non-smoking Asians. In 2024, Dr. Lin was diagnosed with Stage 4 lung cancer, having never smoked in his life. After his diagnosis, Dr. Lin sprung into action. He began receiving care from Dr. Heather Wakelee – a Stanford oncologist specializing in lung cancer. Dr Wakelee is the Deputy Director of the Stanford Cancer Institute, the Division Chief of Medical Oncology, and a leader in the International Association for the Study of Lung Cancer. In this episode, we are privileged to be joined by both Dr. Lin and his oncologist, Dr. Wakelee.Over the course of our conversation, Dr. Lin describes the experience of receiving and living with a diagnosis that has been life changing for both him and his family. He details his remarkable efforts to leverage his diagnosis for the good of patients and rising medical professionals  — and explains how spiritual practices have helped sustain him through this difficult time. Dr. Wakelee shares her approach to first visits with patients facing daunting cancer diagnoses, how she approaches grief, and the unique privilege and challenge of treating a colleague. Together, the doctor and his physician explore the value of hope in cancer, the dangers of false hope, and the importance of maximizing meaning in life — however much time is left. In this episode, you'll hear about: 2:50 - Dr. Lin's experience of being diagnosed with stage 4 lung cancer despite having never smoked14:20 - Dr. Wakelee's approach to first visits with newly diagnosed lung cancer patients25:35 - Dr. Lin's experience of shifting from the mindset of “doctor” to the mindset of “patient” 30:30 - How a doctor's messaging can affect the patient's outlook on their diagnosis43:00 - The common themes prevalent across religions and spiritual orientations that support patients in the navigation of serious illness50:24 - Advice to doctors for finding deeper meaning in medicineListen to Dr. Lin's first appearance on The Doctor's Art. If you enjoyed this episode, please subscribe, rate, and review our show, available for free on Spotify, Apple Podcasts, or wherever you get your podcasts. If you know of a doctor, patient, or anyone working in health care who would love to explore meaning in medicine with us on the show, feel free to leave a suggestion in the comments or send an email to info@thedoctorsart.com.Copyright The Doctor's Art Podcast 2026

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AWM865. CME/MOC/AAPA credit will be available until June 30, 2026.Strategies for Immunotherapy Success in NSCLC: How to Incorporate Modern ICI Platforms Across the Disease Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Bristol Myers Squibb, Merck & Co., Inc., Rahway, NJ, USA, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AWM865. CME/MOC/AAPA credit will be available until June 30, 2026.Strategies for Immunotherapy Success in NSCLC: How to Incorporate Modern ICI Platforms Across the Disease Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Bristol Myers Squibb, Merck & Co., Inc., Rahway, NJ, USA, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AWM865. CME/MOC/AAPA credit will be available until June 30, 2026.Strategies for Immunotherapy Success in NSCLC: How to Incorporate Modern ICI Platforms Across the Disease Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Bristol Myers Squibb, Merck & Co., Inc., Rahway, NJ, USA, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AWM865. CME/MOC/AAPA credit will be available until June 30, 2026.Strategies for Immunotherapy Success in NSCLC: How to Incorporate Modern ICI Platforms Across the Disease Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Bristol Myers Squibb, Merck & Co., Inc., Rahway, NJ, USA, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

CME credits: 0.25 Valid until: 11-12-2024 Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-lung-cancer-breaking-barriers-advances-in-treating-egfr-exon-20-insertions-in-nsclc/16082/ We now have FDA approved targeted therapies to treat NSCLC with EGFR exon 20 insertion mutations. Drs. Wakelee and Bazhenova discuss the most current data on both approved therapies and drugs in development.=

Non-small cell lung cancer was one of the big topics at the 2023 ASCO Annual Meeting where Heather Wakelee, MD, FASCO, Professor of Medicine and Chief of the Division of Oncology at Stanford University in California, was overheard reminding a junior cancer doctor that the only adjuvant therapy for lung cancer had been chemotherapy just a couple of decades previously. Now, a plethora of targeted therapies are available, and Wakelee reported a big improvement in outcome from one of them—pembrolizumab—used both before and after surgery in early Stage II and III disease (mostly Stage III). “These results indicate perioperative pembrolizumab given in combination with chemotherapy prior to surgery and for up to one year as a single agent after surgery led to significant improvement in event-free survival (defined by local progression precluding definitive surgery, recurrence, or death) with a strong trend towards improvement in overall survival. These results indicate peri-operative pembrolizumab significantly improves outcomes for patients with potentially resectable Stage II-III NSCLC,” said Wakelee. After her talk at ASCO, she discussed her group’s findings with OncTimesTalk correspondent, Peter Goodwin.

Wakelee is a band out of Brooklyn consisting of twins Alex and David Bulmer and Elliot Schiang. I found them because of their funny videos on tiktok but they make dope music too Checkout their debut album Wakelee now.

On this week's episode we meet up with the Brooklyn based band WAKELEE. Wakelee consists of identical twins Alex (vocals/guitar) and David Bulmer (drums) and Elliot Shiang (vocals/bass). They met at a friend's show in New York and immediately bonded over Halal food and music. They have since released an EP, a healthy batch of emo-tinged singles, and recently released their self-titled debut album, produced by Brian DiMeglio (Bartees Strange, Superbloom, Grandad) in April 2023. Join Alex, David, Elliot and I as we throw on some “Mood Rings” while we go on a “Nighttime Car Ride” to the life “Arcade.” WAKELEE - “Wakelee”      OUT NOW!!!!!!Thanks for listening!!! Please Follow us on Instagram @hiddentracks99

Plumber here yesterday to fix the things that didn't pass on the FOUR POINT INSPECTION for a lower homeowner's premium.  New shut off valves for all the sinks and the master bath toilet!  They were severely corroded!  Unless you need to shut them off, do you really ever LOOK at them?  Inspecter back tonight!  Hope we pass this time!    The Music Authority Podcast...listen, like, comment, download, share, repeat…heard daily on Podchaser, Deezer, Amazon Music, Audible, Listen Notes, Google Podcast Manager, Mixcloud, Player FM, Stitcher, Tune In, Podcast Addict, Cast Box, Radio Public, and Pocket Cast, and APPLE iTunes!  Follow the show on TWITTER JimPrell@TMusicAuthority!  Please, are you listening? Please, are you sharing the podcast?  Please, has a podcast mention been placed into your social media?  How does and can one listen in? Let me list the ways...*Podcast - https://themusicauthority.transistor.fm/   The Music Authority Podcast!  Special Recorded Network Shows, too!  Different than my daily show! *Radio Candy Radio Monday Wednesday, & Friday 7PM ET, 4PM PT*Rockin' The KOR Tuesday, Wednesday, and Thursday at 7PM UK time, 2PM ET, 11AM PT  www.koradio.rocks*Pop Radio UK Friday, Saturday, & Sunday 6PM UK, 1PM ET, 10AM PT!  *The Sole Of Indie  https://soleofindie.rocks/  Monday Through Friday 6-7PM EST!May 9, 2023, Tuesday, row two…@Mark Johnson & Ramírez Exposure - 04 - When Worlds Collide [Tuning On The Century, Vol 2 (Happy Sparrow)]Joe Dilillo Music - 1 Loser Girl [Superhero Star]The Raging Teens - 05 - That's How I Like It [Rum Bar Rockin' Sampler- Viva Las Vegas 26] (Rum Bar Records)Tony Valentino of the Standells - 01 Try It [Dirty Water Revisited] (Big Stir Records)Damien Binder - 02 Here It Is [Bright Side]Jeremy Porter and The Tucos - 12 Hummingbird Heartbeat [Candy Coated Cannonball]@Adventure Playground - 9 New Plan(et) [Alright Already]The Streetwalkin' Cheetahs - Victim Of The Service Industry [April 2023 Audio Jukebox] (Rum Bar Records)Norwegian Soft Kitten - 10 Eyes Closed [On Loan From The Universe]Emperor Penguin - 09 - Blink [Corporation Pop!] (koolkatmusik.com)@Wakelee - 01 Plinko [Wakelee] (@Bok Choy LLC)@CARUSO - 15 The Long-Haired Girl (1982 Demo Remix) [In the Face 35th Anniversary Deluxe] (Dave Caruso)Kevin Robertson - 07 Wander On [Magic Spells Abound] (Futureman Records)Dolph Chaney - 08 Sideless World [This Is Dolph Chaney] (Big Stir Records)John Wayne Supermarket - 12 Assis La [Les Plus Grands Succès] (Twisted Soul Records)D-Tension - 05 - Other Side of The Road [Tales From The Pub] (Red on Red Records)Paul Callan - 5.Broken birds [Over My Wishes]

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer — Faculty Presentation 1: Management of Metastatic Non-Small Cell Lung Cancer (NSCLC) without an Actionable Mutation — Dr Heather Wakelee CME information and select publications

OFF THE FRET, MORE MUSIC, MORE MUSIC TALK! If you're like ME – MUSIC is everything! Since day one it's been a passion of mine to create an opportunity to showcase amazing up-and-coming artists. The CHRIS COLLINS SHOW has interviewed some of the most incredible international and national bands out there—from Finland, the Philippines, India and UK—to NY, LA, Texas and Nashville—you name it. We are so fortunate to have this outlet to show you guys some of the most talented musicians out there today! There's no other medium that brings people together like LIVE MUSIC. Join me and listen to OFF THE FRET podcast. What's Good!? It's Chris from the Chris Collins Millennial Talk Show. Featuring Brooklyn trio, Wakelee, setting the tone with their debut self titled album “Wakelee”. Lyrics that explore the complexities of human emotion. Joins, Off The Fret more music, more music talk. https://www.wakeleemusic.com

With more than 10 known driver mutations in non-small cell lung cancer (NSCLC), testing is ever more critical, says Heather Wakelee, MD, division chief of medical oncology at Stanford University and president of the International Association for the Study of Lung Cancer. Listen as she and Peer-Spectives host Bob Figlin, MD, the Steven Spielberg Family Chair in Hematology Oncology at Cedars-Sinai Cancer, talk about how she manages patients with metastatic disease or those who need adjuvant treatment, when she starts targeted therapy or immunotherapy, and more. “We can drastically change the course of disease for a patient by giving them the appropriate targeted treatment. So that testing is so critical,” Dr. Wakelee said.

On this episode of Headliners, Greg sits down with WAKELEE to talk about their upcoming self-titled album (OUT 14 APRIL).Formed in Brooklyn in 2019 by Bulmer, his identical twin brother David (drums) and Elliot Shiang (vocals/bass), they met at a friend's show in NYC and immediately bonded over Halal food and indie music. The trio has since released an EP, a healthy batch of emo-tinged singles, including the recently released tracks "Mood Rings," "Everything Under The Sun" and "Outside."CONNECT WITH WAKELEELinktree - Spotify - Instagram - TikTokSUPPORT THIS SHOW

Brooklyn Emo band Wakelee joins STRIKE A CHORD to discuss their upcoming self-titled album, Wakelee. We all saw it and we need to address it. What happened to Rihanna's Super Bowl 2023 HalfTime show? The performance was lackluster at best. BUT what did Howard Stern say that has everyone getting their twitter accounts cancelled—Wakelee has some sage advice for live performances! Alex (vocals/guitar) and David (drums) are identical twins and the triplet that went wrong is Elliot (vocals/bass)—so how do some Jersey bros link up with an Oregon player? This is a first! Urban Dictionary doesn't have a definition for Wakelee. BUT it's the perfect opportunity for the band to provide a backstory on how they named their band—although it's the last place you would expect. The feeling of not knowing how to feel after something bad happens is spot on for Wakelee's single “Mood Rings.” Sometimes we can be a "tin can"—having difficulty processing emotions and expressing feelings is confusing. Should I be angry, sad, mad, happy or glad. Is that profound enough or am I in Oz? Having an identical twin has some advantages. There's a world of possibilities where we can swap roles at any time. BUT does that work with relationships? Enoughs, enough! Time to get this album out and we can't wait to hear what Wakelee delivers. Follow, support and listen: https://www.wakeleemusic.com

Dr Heather Wakelee from Stanford Cancer Institute in Palo Alto, California, discusses the management of localized non-small cell lung cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayLocalizedNSCLC22).

Go online to PeerView.com/HSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) are swiftly transitioning from the metastatic to early-stage settings and are expected to transform the multimodal management of patients with resectable stage I-III NSCLC. Remarkable data have emerged from several trials assessing ICIs and rational combinations as neoadjuvant and/or adjuvant therapies, but many questions remain and misperceptions persist. What are the pros/cons of neoadjuvant versus adjuvant immunotherapy, and how should the best approach be determined for each patient? What is the optimal duration of therapy, and how should responses be assessed? What adverse events should be anticipated, and are perioperative complications higher? This PeerView MasterClass, based on a recent live web broadcast, addresses these and many other essential topics. Watch this engaging discussion about new, practice-changing evidence, debates about implications and applicability to practice, and demonstrations of how to achieve better surgeon–oncologist partnerships to facilitate appropriate incorporation of ICIs into multimodal treatment plans for patients with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Describe the mechanistic aspects of immune checkpoint inhibition, rationale for using immunotherapy as a component of multimodal therapy in earlier stages of lung cancer, and key clinical trials evaluating immunotherapy in these settings, Assess the real evidence and misconceptions related to the safety and adverse effects of checkpoint inhibitors when used in the treatment of patients with locally advanced and early-stage lung cancer as well as potential implications for surgical outcomes in these patients, Apply the latest evidence and guidelines for integrating immunotherapy into multimodal treatment plans in locally advanced and earlier stages of NSCLC, Collaborate with the multidisciplinary team to develop evidence-based, individualized treatment approaches for patients with stage III or earlier lung cancer in the context of clinical practice or clinical trials.

Go online to PeerView.com/HSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) are swiftly transitioning from the metastatic to early-stage settings and are expected to transform the multimodal management of patients with resectable stage I-III NSCLC. Remarkable data have emerged from several trials assessing ICIs and rational combinations as neoadjuvant and/or adjuvant therapies, but many questions remain and misperceptions persist. What are the pros/cons of neoadjuvant versus adjuvant immunotherapy, and how should the best approach be determined for each patient? What is the optimal duration of therapy, and how should responses be assessed? What adverse events should be anticipated, and are perioperative complications higher? This PeerView MasterClass, based on a recent live web broadcast, addresses these and many other essential topics. Watch this engaging discussion about new, practice-changing evidence, debates about implications and applicability to practice, and demonstrations of how to achieve better surgeon–oncologist partnerships to facilitate appropriate incorporation of ICIs into multimodal treatment plans for patients with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Describe the mechanistic aspects of immune checkpoint inhibition, rationale for using immunotherapy as a component of multimodal therapy in earlier stages of lung cancer, and key clinical trials evaluating immunotherapy in these settings, Assess the real evidence and misconceptions related to the safety and adverse effects of checkpoint inhibitors when used in the treatment of patients with locally advanced and early-stage lung cancer as well as potential implications for surgical outcomes in these patients, Apply the latest evidence and guidelines for integrating immunotherapy into multimodal treatment plans in locally advanced and earlier stages of NSCLC, Collaborate with the multidisciplinary team to develop evidence-based, individualized treatment approaches for patients with stage III or earlier lung cancer in the context of clinical practice or clinical trials.

Go online to PeerView.com/HSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) are swiftly transitioning from the metastatic to early-stage settings and are expected to transform the multimodal management of patients with resectable stage I-III NSCLC. Remarkable data have emerged from several trials assessing ICIs and rational combinations as neoadjuvant and/or adjuvant therapies, but many questions remain and misperceptions persist. What are the pros/cons of neoadjuvant versus adjuvant immunotherapy, and how should the best approach be determined for each patient? What is the optimal duration of therapy, and how should responses be assessed? What adverse events should be anticipated, and are perioperative complications higher? This PeerView MasterClass, based on a recent live web broadcast, addresses these and many other essential topics. Watch this engaging discussion about new, practice-changing evidence, debates about implications and applicability to practice, and demonstrations of how to achieve better surgeon–oncologist partnerships to facilitate appropriate incorporation of ICIs into multimodal treatment plans for patients with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Describe the mechanistic aspects of immune checkpoint inhibition, rationale for using immunotherapy as a component of multimodal therapy in earlier stages of lung cancer, and key clinical trials evaluating immunotherapy in these settings, Assess the real evidence and misconceptions related to the safety and adverse effects of checkpoint inhibitors when used in the treatment of patients with locally advanced and early-stage lung cancer as well as potential implications for surgical outcomes in these patients, Apply the latest evidence and guidelines for integrating immunotherapy into multimodal treatment plans in locally advanced and earlier stages of NSCLC, Collaborate with the multidisciplinary team to develop evidence-based, individualized treatment approaches for patients with stage III or earlier lung cancer in the context of clinical practice or clinical trials.

Go online to PeerView.com/HSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) are swiftly transitioning from the metastatic to early-stage settings and are expected to transform the multimodal management of patients with resectable stage I-III NSCLC. Remarkable data have emerged from several trials assessing ICIs and rational combinations as neoadjuvant and/or adjuvant therapies, but many questions remain and misperceptions persist. What are the pros/cons of neoadjuvant versus adjuvant immunotherapy, and how should the best approach be determined for each patient? What is the optimal duration of therapy, and how should responses be assessed? What adverse events should be anticipated, and are perioperative complications higher? This PeerView MasterClass, based on a recent live web broadcast, addresses these and many other essential topics. Watch this engaging discussion about new, practice-changing evidence, debates about implications and applicability to practice, and demonstrations of how to achieve better surgeon–oncologist partnerships to facilitate appropriate incorporation of ICIs into multimodal treatment plans for patients with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Describe the mechanistic aspects of immune checkpoint inhibition, rationale for using immunotherapy as a component of multimodal therapy in earlier stages of lung cancer, and key clinical trials evaluating immunotherapy in these settings, Assess the real evidence and misconceptions related to the safety and adverse effects of checkpoint inhibitors when used in the treatment of patients with locally advanced and early-stage lung cancer as well as potential implications for surgical outcomes in these patients, Apply the latest evidence and guidelines for integrating immunotherapy into multimodal treatment plans in locally advanced and earlier stages of NSCLC, Collaborate with the multidisciplinary team to develop evidence-based, individualized treatment approaches for patients with stage III or earlier lung cancer in the context of clinical practice or clinical trials.

Go online to PeerView.com/HSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) are swiftly transitioning from the metastatic to early-stage settings and are expected to transform the multimodal management of patients with resectable stage I-III NSCLC. Remarkable data have emerged from several trials assessing ICIs and rational combinations as neoadjuvant and/or adjuvant therapies, but many questions remain and misperceptions persist. What are the pros/cons of neoadjuvant versus adjuvant immunotherapy, and how should the best approach be determined for each patient? What is the optimal duration of therapy, and how should responses be assessed? What adverse events should be anticipated, and are perioperative complications higher? This PeerView MasterClass, based on a recent live web broadcast, addresses these and many other essential topics. Watch this engaging discussion about new, practice-changing evidence, debates about implications and applicability to practice, and demonstrations of how to achieve better surgeon–oncologist partnerships to facilitate appropriate incorporation of ICIs into multimodal treatment plans for patients with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Describe the mechanistic aspects of immune checkpoint inhibition, rationale for using immunotherapy as a component of multimodal therapy in earlier stages of lung cancer, and key clinical trials evaluating immunotherapy in these settings, Assess the real evidence and misconceptions related to the safety and adverse effects of checkpoint inhibitors when used in the treatment of patients with locally advanced and early-stage lung cancer as well as potential implications for surgical outcomes in these patients, Apply the latest evidence and guidelines for integrating immunotherapy into multimodal treatment plans in locally advanced and earlier stages of NSCLC, Collaborate with the multidisciplinary team to develop evidence-based, individualized treatment approaches for patients with stage III or earlier lung cancer in the context of clinical practice or clinical trials.

Go online to PeerView.com/HSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) are swiftly transitioning from the metastatic to early-stage settings and are expected to transform the multimodal management of patients with resectable stage I-III NSCLC. Remarkable data have emerged from several trials assessing ICIs and rational combinations as neoadjuvant and/or adjuvant therapies, but many questions remain and misperceptions persist. What are the pros/cons of neoadjuvant versus adjuvant immunotherapy, and how should the best approach be determined for each patient? What is the optimal duration of therapy, and how should responses be assessed? What adverse events should be anticipated, and are perioperative complications higher? This PeerView MasterClass, based on a recent live web broadcast, addresses these and many other essential topics. Watch this engaging discussion about new, practice-changing evidence, debates about implications and applicability to practice, and demonstrations of how to achieve better surgeon–oncologist partnerships to facilitate appropriate incorporation of ICIs into multimodal treatment plans for patients with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Describe the mechanistic aspects of immune checkpoint inhibition, rationale for using immunotherapy as a component of multimodal therapy in earlier stages of lung cancer, and key clinical trials evaluating immunotherapy in these settings, Assess the real evidence and misconceptions related to the safety and adverse effects of checkpoint inhibitors when used in the treatment of patients with locally advanced and early-stage lung cancer as well as potential implications for surgical outcomes in these patients, Apply the latest evidence and guidelines for integrating immunotherapy into multimodal treatment plans in locally advanced and earlier stages of NSCLC, Collaborate with the multidisciplinary team to develop evidence-based, individualized treatment approaches for patients with stage III or earlier lung cancer in the context of clinical practice or clinical trials.

Go online to PeerView.com/HSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) are swiftly transitioning from the metastatic to early-stage settings and are expected to transform the multimodal management of patients with resectable stage I-III NSCLC. Remarkable data have emerged from several trials assessing ICIs and rational combinations as neoadjuvant and/or adjuvant therapies, but many questions remain and misperceptions persist. What are the pros/cons of neoadjuvant versus adjuvant immunotherapy, and how should the best approach be determined for each patient? What is the optimal duration of therapy, and how should responses be assessed? What adverse events should be anticipated, and are perioperative complications higher? This PeerView MasterClass, based on a recent live web broadcast, addresses these and many other essential topics. Watch this engaging discussion about new, practice-changing evidence, debates about implications and applicability to practice, and demonstrations of how to achieve better surgeon–oncologist partnerships to facilitate appropriate incorporation of ICIs into multimodal treatment plans for patients with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Describe the mechanistic aspects of immune checkpoint inhibition, rationale for using immunotherapy as a component of multimodal therapy in earlier stages of lung cancer, and key clinical trials evaluating immunotherapy in these settings, Assess the real evidence and misconceptions related to the safety and adverse effects of checkpoint inhibitors when used in the treatment of patients with locally advanced and early-stage lung cancer as well as potential implications for surgical outcomes in these patients, Apply the latest evidence and guidelines for integrating immunotherapy into multimodal treatment plans in locally advanced and earlier stages of NSCLC, Collaborate with the multidisciplinary team to develop evidence-based, individualized treatment approaches for patients with stage III or earlier lung cancer in the context of clinical practice or clinical trials.

Go online to PeerView.com/HSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) are swiftly transitioning from the metastatic to early-stage settings and are expected to transform the multimodal management of patients with resectable stage I-III NSCLC. Remarkable data have emerged from several trials assessing ICIs and rational combinations as neoadjuvant and/or adjuvant therapies, but many questions remain and misperceptions persist. What are the pros/cons of neoadjuvant versus adjuvant immunotherapy, and how should the best approach be determined for each patient? What is the optimal duration of therapy, and how should responses be assessed? What adverse events should be anticipated, and are perioperative complications higher? This PeerView MasterClass, based on a recent live web broadcast, addresses these and many other essential topics. Watch this engaging discussion about new, practice-changing evidence, debates about implications and applicability to practice, and demonstrations of how to achieve better surgeon–oncologist partnerships to facilitate appropriate incorporation of ICIs into multimodal treatment plans for patients with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Describe the mechanistic aspects of immune checkpoint inhibition, rationale for using immunotherapy as a component of multimodal therapy in earlier stages of lung cancer, and key clinical trials evaluating immunotherapy in these settings, Assess the real evidence and misconceptions related to the safety and adverse effects of checkpoint inhibitors when used in the treatment of patients with locally advanced and early-stage lung cancer as well as potential implications for surgical outcomes in these patients, Apply the latest evidence and guidelines for integrating immunotherapy into multimodal treatment plans in locally advanced and earlier stages of NSCLC, Collaborate with the multidisciplinary team to develop evidence-based, individualized treatment approaches for patients with stage III or earlier lung cancer in the context of clinical practice or clinical trials.

In this episode of Lung Cancer Considered , Dr. Heather Wakelee and Dr. Paul Van Schil join hosts Dr. Narjust Duma and Dr. Stephen Liu to discuss priorities and initiatives for IASLC in the 2021-22 year. Dr. Wakelee takes the reins as President of the IASLC this month during WCLC, the second woman to achieve this honor. Dr. Van Schil begins his term as President-Elect of the IASLC during WCLC, too.

The American Society of Clinical Oncology meeting just concluded and Lung Cancer Considered has a summary of the meeting, with a unique lung cancer focus. Tune in as host Stephen Liu and guests Dr. Alfredo Addeo and Dr. Heather Wakelee discuss key findings from ASCO 2021.

There are plans to build a motel off Route 8 on Wakelee Avenue in Ansonia. Click play to listen to people react.

The latest episode of Lung Cancer Considered discusses women in thoracic oncology and the upcoming IASLC Women in Thoracic Oncology Event. Register now for this event. This episode features a conversation between host, Dr. Narjust Duma, and Dr. Heather Wakelee and Dr. Clarissa Mathias. Dr. Wakelee is a thoracic medical oncologist, Deputy Director of the Stanford Cancer Institute and is the Division Chief of Medical Oncology at Stanford University Medical Center. She is also the president-elect of the IASLC. Dr. Clarissa Mathias, Medical Oncologist at Grupo Oncoclinicas, is president of the Brazilian Society of Medical Oncology, Chair of the ASCO International Committee and a member of the IASLC Board of Directors. Together they discuss their career paths and what they are looking forward to at the Virtual Women in Thoracic Oncology Event hosted by IASLC on January 20th.

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California. In this series, the doctors discuss a series of cases related to EGFR Mutations. In this case, the discussion surrounds patient progression in a case with EGFR mutation, and what are the next steps. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California. In this series, the doctors discuss a series of cases related to EGFR Mutations. In this case, the discussion surrounds a case with an EGFR Mutation and High PDL1. The discussion centers around the role of immunotherapy in treatment decisions. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California. In this series, the doctors discuss a series of cases related to EGFR Mutations. In this case, the discussion surrounds an EGFR mutation with MET amplification. They review treatment decisions and the importance of the level of MET amplification.For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California. In this series, the doctors discuss a series of cases related to EGFR Mutations. In this discussion they review the recommended treatment for a common EGFR mutation. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California. In this series, the doctors discuss a series of cases related to EGFR Mutations. In this case, the discussion surrounds an EGFR mutation treated with Tagrisso, and progression while on treatment. The doctors also discuss the role of repeat biopsy. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California. In this series, the doctors discuss a series of cases related to EGFR Mutations - is there a place for chemotherapy and an EGFR inhibitor concurrently or sequentially in treatment decisions?For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California. In this series, the doctors discuss a series of cases related to EGFR Mutations - is there a place for chemotherapy and an EGFR inhibitor concurrently or sequentially in treatment decisions?For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

A Roundtable Discussion Featuring Justin F Gainor, MD, Matthew Gubens, MD, MS, Geoffrey R Oxnard, MD, Heather Wakelee, MD, Isaac Levy, MD and Estelamari Rodriguez, MD, MPH moderated by Neil Love, MD. Produced by Research To Practice.

Biomarker Assessment and Targeted Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC) — Slide Presentation 3: Optimal Approach to Metastatic NSCLC with an EGFR Tumor Mutation After Disease Progression on Osimertinib — Dr Wakelee. CME information and select publications

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California. In this series, the doctors discuss a series of cases related to an EGFR mutation. In this podcast, the discussion is regarding uncommon EXON 20 mutation, suggested treatments, targeted therapy and clinical trials. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California. In this series, the doctors discuss a series of cases related to EGFR Mutations. For EGFR mutations and the FLAURA trial, is there a difference in data based on demographics and how can that effect treatment decisions? For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

This week on the podcast we're talking to RA member Matt Wakelee - we talk about his experience in youth sports, his past job as a manager at Michaels, his college experience and his focus on Olympic Weightlifting. Thanks for listening - give us a share, leave us a like/review wherever you listen to podcasts, and let us know what you want to see in future episodes! Romeo Athletics is New England's premier coach-led gym for functional fitness and athletic performance. We're here to help you lose fat, gain muscle, and transform your body into a healthy, head-turning work of art. Learn more about the gym: https://romeoathletics.fitness/ Find us on Instagram: @RomeoAthletics and @EBourcier

Dr. Heather Wakelee thoracic medical oncologist and professor of medicine at Stanford University Medical Center and president-elect of IASLC and Corinne Faivre-Finn professor of thoracic radition oncology at the University of Manchester in the UK and honorary consultant clinical oncologist joined Dr. Jack West at the IASLC World Conference on Lung Cancer in Barcelona, Spain to discuss women leadership in oncology and medicine.

Drs. Heather Wakelee and Jack West review how she entered & became a leader in thoracic oncology, her prioritization of mentorship, & her efforts to continue the strong momentum of the International Association of the Study of Lung Cancer (IASLC).

Drs. Heather Wakelee and Jack West review how she entered & became a leader in thoracic oncology, her prioritization of mentorship, & her efforts to continue the strong momentum of the International Association of the Study of Lung Cancer (IASLC).

IASLC CEO Dave Mesko sits down with IASLC President-Elect candidate, Dr. Heather Wakelee, Professor of Medicine, Oncology at Stanford University in Stanford, California. Voting is available to active IASLC members and ends at 11:59 Eastern Time on June 26, 2019. Vote at directvote.net/IASLC.

Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Interview with Heather Wakelee, MD conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/MorbidityMortality17 - A roundtable discussion featuring Heather Wakelee, MD, Maria Picton, MD and Estelamari Rodriguez, MD, MPH. Moderated by Neil Love, MD. Produced by Research To Practice.

Dr. Heather Wakelee, Stanford University Medical Center, evaluates the lack of evidence for the use of targeted therapies after surgery, and describes ongoing trials attempting to resolve that issue.

Dr. Heather Wakelee, Stanford University Medical Center, evaluates the lack of evidence for the use of targeted therapies after surgery, and describes ongoing trials attempting to resolve that issue.